F. Michael Ball has been promoted as president of Allergan after 10 years with the company. As executive vice president and president of its pharmaceuticals division since 2003, he has been instrumental in the reorganization of global commercial operations. David E.I. Pyott remains as chairman and chief executive of the group. Raymond Diradoorian, who has been with the company for 25 years, gets promoted as executive vice president in charge of global technical operations. Allergan recorded adjusted net earnings of $441.5 million in 2005, up from $368.8 million in the previous year, as total revenues increased to $2,319 million from $2,046 million. Sales of eye care pharmaceuticals were up by 16.2 percent to $1,321.7 million, with a 15.0 percent increase in terms of local currencies.